Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 4/20 | 0.74 |
| ▸ | SLC5A1 | P13866 | 6/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 2/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.48 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942070 | 0.91 | SLC28A3 (0.71) | SLC28A3SLC5A1HIF1ATYRSLC5A2 | |
| SCHEMBL940443 | 0.88 | SLC28A3 (0.78) | SLC28A3SLC5A1HIF1ATYR | |
| SCHEMBL940116 | 0.85 | SLC28A3 (0.81) | SLC28A3SLC5A1HIF1ATYRSLC5A2 | |
| SCHEMBL940531 | 0.85 | SLC28A3 (0.73) | SLC28A3SLC5A1HIF1ACA12CA1 | |
| SCHEMBL941049 | 0.85 | SLC28A3 (0.60) | SLC28A3SLC5A1HIF1ATYRSLC5A2 | |
| SCHEMBL4636160 | 0.84 | SLC28A3 (0.58) | SLC28A3SLC5A1HIF1ACA12CA1 | |
| SCHEMBL23031052 | 0.81 | SLC28A3 (0.70) | SLC28A3SLC5A1HIF1ATYRSLC5A2 | |
| SCHEMBL4367622 | 0.81 | SLC28A3 (0.70) | SLC28A3SLC5A1HIF1ATYRSLC5A2 | |
| Curculigoside B SCHEMBL7953777 | 0.81 | SLC28A3 (0.60) | SLC28A3SLC5A1HIF1ATYRSLC5A2 | |
| Curculigoside B SCHEMBL29419859 | 0.81 | SLC28A3 (0.60) | SLC28A3SLC5A1HIF1ATYRSLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1932514-B1 | PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR | EZAKI GLICO CO (JP) | 2018-11-14 | — | — | EP | disclosed |
| US-20140023602-A1 | EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE | EZAKI GLICO CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | DSM IP ASSETS B.V. (NL) | 2011-01-20 | — | — | US | disclosed |
| US-20080274068-A1 | External Preparation for Skin Containing a Phosphorlated Saccharide | EZAKI GLICO CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1932514-A1 | PHARMACEUTICAL PREPARATION FOR EXTERNAL APPLICATION TO SKIN COMPRISING PHOSPHORYLATED SUGAR | Ezaki Glico Co., Ltd. (JP) | 2008-06-18 | — | — | EP | disclosed |
| EP-1859835-A2 | Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside | PENTAPHARM Ltd. (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20030198610-A1 | Topical agent for dermatological use | DSM IP ASSETS B.V. (NL) | 2003-10-23 | — | — | US | disclosed |
| EP-0649648-B1 | Skin whitening agents containing glycosides | SHISEIDO CO LTD (JP) | 2001-09-19 | — | — | EP | disclosed |
| US-5700784-A | GLYCOSIDES OF HYDROXYSALICYLIC ACID AND/OR GLYCOSIDES OF ESTERS OF HYDROXYSALICYLIC ACID; EXCELLENT WHITENING EFFECT AND SKIN CARE EFFECT | SHISEIDO CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| EP-0649648-A2 | Skin whitening agents containing glycosides | SHISEIDO COMPANY LIMITED (JP) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014141-A1 | TOPICAL AGENT FOR DERMATOLOGICAL USE | GALE, ALPP, UGGT1 | SLC28A3 2245/4885SLC5A1 1371/4885HIF1A 889/4885 |
| US-20140023602-A1 | EXTERNAL PREPARATION FOR SKIN CONTAINING A PHOSPHORYLATED SACCHARIDE | SI, CUTA, CD44 | SLC28A3 1164/4885SLC5A1 723/4885HIF1A 634/4885 |
| US-20030198610-A1 | Topical agent for dermatological use | GALE, UGGT1, UGDH | SLC28A3 2040/4885SLC5A1 1242/4885HIF1A 1140/4885 |
| US-20080274068-A1 | External Preparation for Skin Containing a Phosphorlated Saccharide | CUTA, SI, CD44 | SLC28A3 977/4885SLC5A1 589/4885HIF1A 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.